Apheon Bioscience — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Apheon Bioscience is a private, preclinical biotech founded in 2020, headquartered in Cambridge, Massachusetts. The company is developing targeted immunotherapies for oncology and women's health indications, including Triple-Negative Breast Cancer (TNBC), Leiomyosarcoma, and Endometriosis, utilizing its proprietary ApheGenixID™ antigen discovery and antibody engineering platform. Its strategy combines internal asset development with a fee-for-service and partnership model, offering precision DNA cloning and antibody discovery services to other biopharma entities. Apheon is currently pre-revenue and is led by a team with deep expertise in molecular biology and immunology, seeking strategic partnerships and investment to advance its pipeline.

OncologyWomen's Health

Technology Platform

ApheGenixID™ discovery platform for identifying tumor-associated antigens and recovering high-affinity antibody leads, integrated with a precision recombinant antibody engineering suite featuring AI-driven design and high-throughput screening.

Opportunities

The company addresses large, underserved markets in women's health oncology (TNBC, Leiomyosarcoma) and chronic disease (Endometriosis) with a novel immunotherapy approach.

Its U.S.-based, BIOSECURE-compliant service platform also taps into growing demand for secure, flexible R&D outsourcing, providing a potential revenue stream to fund internal pipeline development.

Risk Factors

All internal therapeutic programs are in high-risk preclinical stages with no clinical validation.

The company's dual business model (services and proprietary R&D) presents execution challenges, and its novel platform must be validated through successful partnerships or pipeline advancement in a highly competitive field.

Competitive Landscape

Apheon competes in the crowded antibody discovery platform space against large CROs (e.g., Abzena, Ligand) and specialized biotechs. Its focus on women's health immunotherapies is a differentiator, but it faces competition from numerous oncology-focused biotechs and larger pharma companies pursuing similar indications with more advanced assets.

More companies in Biologics / Biosimilars →More companies in United States →